CD22 (E7L6Z) Rabbit mAb

CD22 (also known as siglec-2) is a member of the sialic acid-binding immunoglobulin-type lectin (Siglec) family of immunomodulatory receptors. CD22 can bind to its ligand α 2,6-linked sialic acid on different cells (trans interaction) as well as on the same cells (cis interaction). CD22 is predominantly expressed on B cells and functions as an inhibitory co-receptor for the B cell receptor (BCR) (1,2). After BCR ligation, the tyrosine kinase Lyn is activated and phosphorylates two distal of the four ITIM motifs in the intracellular carboxy-terminal region of CD22, which then recruit tyrosine phosphatases, including SHP-1, to the plasma membrane, and in turn, they get tyrosine-phosphorylated and activated to damp the signaling pathways initiated by BCR ligation (3,4). CD22 has been actively pursued as a therapeutic target for autoimmune diseases (5). Due to almost exclusive expression on B cells, it is also actively pursued as a therapeutic target for multiple B cell malignancies (6-8). 1.Nitschke, L. (2009) Immunol Rev 230, 128-43. 2.Meyer, S.J. et al. (2018) Front Immunol 9, 2820. 3.Clark, E.A. and Giltiay, N.V. (2018) Front Immunol 9, 2235. 4.Enterina, J.R. et al. (2019) Biomed J 42, 218-32. 5.Tsubata, T. (2019) Immunol Med 42, 108-16. 6.Ai, J. and Advani, A. (2015) Br J Haematol 168, 471-80. 7.Yurkiewicz, I.R. et al. (2018) Drug Des Devel Ther 12, 2293-300. 8.Pehlivan, K.C. et al. (2018) Curr Hematol Malig Rep 13, 396-406.